|
1
|
Harbeck N and Gnant M: Breast cancer.
Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pondé NF, Zardavas D and Piccart M:
Progress in adjuvant systemic therapy for breast cancer. Nat Rev
Clin Oncol. 16:27–44. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeMichele A, Yee D and Esserman L:
Mechanisms of resistance to neoadjuvant chemotherapy in breast
cancer. N Engl J Med. 377:2287–2289. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jordan MA and Wilson L: Microtubules as a
target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weaver BA: How Taxol/paclitaxel kills
cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Herbst RS and Khuri FR: Mode of action of
docetaxel-a basis for combination with novel anticancer agents.
Cancer Treat Rev. 29:407–415. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pucci P, Rescigno P, Sumanasuriya S, de
Bono J and Crea F: Hypoxia and noncoding rnas in taxane resistance.
Trends Pharmacol Sci. 39:695–709. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Palmieri C, Krell J, James CR,
Harper-Wynne C, Misra V, Cleator S and Miles D: Rechallenging with
anthracyclines and taxanes in metastatic breast cancer. Nat Rev
Clin Oncol. 7:561–574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Turner N, Biganzoli L and Di Leo A:
Continued value of adjuvant anthracyclines as treatment for early
breast cancer. Lancet Oncol. 16:e362–e369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vaidyanathan A, Sawers L, Gannon AL,
Chakravarty P, Scott AL, Bray SE, Ferguson MJ and Smith G: ABCB1
(MDR1) induction defines a common resistance mechanism in
paclitaxel- and olaparib-resistant ovarian cancer cells. Br J
Cancer. 115:431–441. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Poruchynsky MS, Komlodi-Pasztor E, Trostel
S, Wilkerson J, Regairaz M, Pommier Y, Zhang X, Kumar Maity T,
Robey R, Burotto M, et al: Microtubule-targeting agents augment the
toxicity of DNA-damaging agents by disrupting intracellular
trafficking of DNA repair proteins. Proc Natl Acad Sci USA.
112:1571–1576. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang J, Yu Y, Liu W, Li Z, Wei Z and Jiang
R: Microtubule-associated protein tau is associated with the
resistance to docetaxel in prostate cancer cell lines. Res Rep
Urol. 9:71–77. 2017.PubMed/NCBI
|
|
13
|
Du Q, Taylor L, Compton DA and Macara IG:
LGN blocks the ability of NuMA to bind and stabilize microtubules.
A mechanism for mitotic spindle assembly regulation. Curr Biol.
12:1928–1933. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mochizuki N, Cho G, Wen B and Insel PA:
Identification and cDNA cloning of a novel human mosaic protein,
LGN, based on interaction with G alpha i2. Gene. 181:39–43. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fukukawa C, Ueda K, Nishidate T, Katagiri
T and Nakamura Y: Critical roles of LGN/GPSM2 phosphorylation by
PBK/TOPK in cell division of breast cancer cells. Genes Chromosomes
Cancer. 49:861–872. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He XQ, Zhang YF, Yu JJ, Gan YY, Han NN,
Zhang MX, Ge W, Deng JJ, Zheng YF and Xu XM: High expression of
G-protein signaling modulator 2 in hepatocellular carcinoma
facilitates tumor growth and metastasis by activating the PI3K/AKT
signaling pathway. Tumour Biol. 39:1–10. 2017. View Article : Google Scholar
|
|
17
|
Barrett T, Troup DB, Wilhite SE, Ledoux P,
Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M,
Marshall KA, et al: NCBI GEO: Archive for high-throughput
functional genomic data. Nucleic Acids Res. 37:D885–D890. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hatzis C, Pusztai L, Valero V, Booser DJ,
Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, et
al: A genomic predictor of response and survival following
taxane-anthracycline chemotherapy for invasive breast cancer. JAMA.
305:1873–1881. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Horak CE, Pusztai L, Xing G, Trifan OC,
Saura C, Tseng LM, Chan S, Welcher R and Liu D: Biomarker analysis
of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone
or paclitaxel in early-stage breast cancer. Clin Cancer Res.
19:1587–1595. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shoemaker RH: The NCI60 human tumour cell
line anticancer drug screen. Nat Rev Cancer. 6:813–823. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Deng M, Yu R, Wang S, Zhang Y, Li Z, Song
H, Liu B, Xu L, Wang X, Zhang Z, et al: Limb-bud and heart
attenuates growth and invasion of human lung adenocarcinoma cells
and predicts survival outcome. Cell Physiol Biochem. 47:223–234.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rao DD, Vorhies JS, Senzer N and
Nemunaitis J: siRNA vs. shRNA: Similarities and differences. Adv
Drug Deliv Rev. 61:746–759. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jasra S and Anampa J: Anthracycline use
for early stage breast cancer in the modern era: A review. Curr
Treat Options Oncol. 19:302018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ueno NT and Mamounas EP: Neoadjuvant
nab-paclitaxel in the treatment of breast cancer. Breast Cancer Res
Treat. 156:427–440. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Morin X, Jaouen F and Durbec P: Control of
planar divisions by the G-protein regulator LGN maintains
progenitors in the chick neuroepithelium. Nat Neurosci.
10:1440–1448. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Culurgioni S, Mari S, Bonetti P, Gallini
S, Bonetto G, Brennich M, Round A, Nicassio F and Mapelli M:
Insc:LGN tetramers promote asymmetric divisions of mammary stem
cells. Nat Commun. 9:10252018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu X, Wang J and Sun G: Identification of
key genes and pathways in renal cell carcinoma through expression
profiling data. Kidney Blood Press Res. 40:288–297. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nowakowska A and Tarasiuk J: Invasion and
metastasis of tumour cells resistant to chemotherapy. Postepy Hig
Med Dosw (Online). 71:380–397. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kaur R, Kaur G, Gill RK, Soni R and
Bariwal J: Recent developments in tubulin polymerization
inhibitors: An overview. Eur J Med Chem. 87:89–124. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wiser O, Qian X, Ehlers M, Ja WW, Roberts
RW, Reuveny E, Jan YN and Jan LY: Modulation of basal and
receptor-induced GIRK potassium channel activity and neuronal
excitability by the mammalian PINS homolog LGN. Neuron. 50:561–573.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Churchill CD, Klobukowski M and Tuszynski
JA: Elucidating the mechanism of action of the clinically approved
taxanes: A comprehensive comparison of local and allosteric
effects. Chem Biol Drug Des. 86:1253–1266. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Needleman DJ, Ojeda-Lopez MA, Raviv U,
Ewert K, Miller HP, Wilson L and Safinya CR: Radial compression of
microtubules and the mechanism of action of taxol and associated
proteins. Biophys J. 89:3410–3423. 2005. View Article : Google Scholar : PubMed/NCBI
|
